Skip to content

TG Therapeutics TGTX Payments For Repurchase Of Equity

Payments For Repurchase Of Equity at other companies

ACM Research logo
ACM ResearchACMR
$1.75M
Evercore logo
EvercoreEVR
$621.35M+53.2%
Bentley Systems, Incorporated logo
Bentley Systems, IncorporatedBSY
$14.23M+50.8%
Monolithic Power Systems logo
Monolithic Power SystemsMPWR
$1.92M-98.8%
AECOM logo
AECOMACM
$30.3M+5,960%
Progressive logo
ProgressivePGR
$435M

Other financials

Income statement

See full
Revenue$204.9M+69.6%
Gross profit$171.4M+62.8%
Operating income$34.8M+304%
Net income$19.8M+291%
EPS (diluted)$0.12+300%

Balance sheet

See full
Cash & equivalents$442.2M+235%
Total debt$753.6M+197%
Total equity$583.1M+146%
Total assets$1.5B+133%

Cash flow

See full
Operating cash flow-$17.9M+37.7%
CapEx$51.0K+104%
Free cash flow-$17.9M+37.6%

Valuation

See full
Market cap$8.15B-14.3%
Enterprise value$8.46B-11.1%
P/E17.6×-225×
P/S11.6×-13.0×

Profitability

See full
Gross margin83.1%-4.4pp
Operating margin21.3%+5.9pp
Net margin66%+55.8pp
FCF margin-6,328.4%+4,773pp

Returns & leverage

See full
Return on equity112.6%+92.9pp
Debt / equity1.3×+0.2×
Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfEquity.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's payments for repurchase of equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TG Therapeutics's payments for repurchase of equity?
TG Therapeutics (TGTX) reported payments for repurchase of equity of $99.99M in Q1 2026.
How has TG Therapeutics's payments for repurchase of equity changed year-over-year?
TG Therapeutics's payments for repurchase of equity increased by 1533.1% year-over-year, from $6.12M to $99.99M.